Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
Standard
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. / Eiermann, Wolfgang; Pienkowski, Tadeusz; Crown, John; Sadeghi, Saeed; Martin, Miguel; Chan, Arlene; Saleh, Mansoor; Sehdev, Sandeep; Provencher, Louise; Semiglazov, Vladimir; Press, Michael; Sauter, Guido; Lindsay, Mary-Ann; Riva, Alessandro; Buyse, Marc; Drevot, Philippe; Taupin, Henry; Mackey, John R.
In: J CLIN ONCOL, Vol. 29, No. 29, 29, 2011, p. 3877-3884.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
AU - Eiermann, Wolfgang
AU - Pienkowski, Tadeusz
AU - Crown, John
AU - Sadeghi, Saeed
AU - Martin, Miguel
AU - Chan, Arlene
AU - Saleh, Mansoor
AU - Sehdev, Sandeep
AU - Provencher, Louise
AU - Semiglazov, Vladimir
AU - Press, Michael
AU - Sauter, Guido
AU - Lindsay, Mary-Ann
AU - Riva, Alessandro
AU - Buyse, Marc
AU - Drevot, Philippe
AU - Taupin, Henry
AU - Mackey, John R
PY - 2011
Y1 - 2011
N2 - Anthracyclines, taxanes, and alkylating agents are among the most active agents in treatment of adjuvant breast cancer (BC), but the optimal schedule for their administration is unknown. We performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) with the combination regimen of TAC.
AB - Anthracyclines, taxanes, and alkylating agents are among the most active agents in treatment of adjuvant breast cancer (BC), but the optimal schedule for their administration is unknown. We performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) with the combination regimen of TAC.
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Lymphatic Metastasis
KW - Follow-Up Studies
KW - Chemotherapy, Adjuvant
KW - Drug Administration Schedule
KW - Cyclophosphamide/administration & dosage
KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
KW - Breast Neoplasms/drug therapy/enzymology/pathology
KW - Doxorubicin/administration & dosage
KW - Receptor, Epidermal Growth Factor/biosynthesis
KW - Taxoids/administration & dosage
KW - Adult
KW - Humans
KW - Aged
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Lymphatic Metastasis
KW - Follow-Up Studies
KW - Chemotherapy, Adjuvant
KW - Drug Administration Schedule
KW - Cyclophosphamide/administration & dosage
KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
KW - Breast Neoplasms/drug therapy/enzymology/pathology
KW - Doxorubicin/administration & dosage
KW - Receptor, Epidermal Growth Factor/biosynthesis
KW - Taxoids/administration & dosage
M3 - SCORING: Journal article
VL - 29
SP - 3877
EP - 3884
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 29
M1 - 29
ER -